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Abstract: Age-related macular degeneration (AMD) leads to irreversible visual loss, therefore, early
intervention is desirable, but due to its multifactorial nature, diagnosis of early disease might be
challenging. Identification of early markers for disease development and progression is key for
disease diagnosis. Suitable biomarkers can potentially provide opportunities for clinical intervention
at a stage of the disease when irreversible changes are yet to take place. One of the most metabolically
active tissues in the human body is the retina, making the use of hypothesis-free techniques, like
metabolomics, to measure molecular changes in AMD appealing. Indeed, there is increasing evidence
that metabolic dysfunction has an important role in the development and progression of AMD.
Therefore, metabolomics appears to be an appropriate platform to investigate disease-associated
biomarkers. In this review, we explored what is known about metabolic changes in the retina,
in conjunction with the emerging literature in AMD metabolomics research. Methods for metabolic
biomarker identification in the eye have also been discussed, including the use of tears, vitreous,
and aqueous humor, as well as imaging methods, like fluorescence lifetime imaging, that could be
translated into a clinical diagnostic tool with molecular level resolution.
Keywords: age-related macular degeneration; metabolomics; metabolism; biomarkers; drusen; retinal
pigment epithelium
1. Introduction
Age-related macular degeneration (AMD) accounts for 8.7% of the world’s total blindness and
is the leading cause of irreversible visual impairment in the Western world of people aged 65 and
older [1,2]. The total number of individuals with this condition is expected to rise to 196 million by
2020 and 288 million by 2040 [2]. Choroidal neovascularization (CNV) is the most aggressive form
of advanced AMD and results in the rapid loss of central vision. The other form of advanced AMD,
geographic atrophy (GA), is characterized by the progressive loss of central vision due to the death of
retinal pigment epithelium (RPE) and photoreceptor cells. At early stages of AMD, accumulation of
intracellular lipofuscin in the RPE and the build-up of extracellular deposits under the RPE occurs [3].
Treatment strategies are available for CNV, but not for GA. Antibodies against vascular endothelial
growth factor (VEGF) can halt progression of CNV, but the effect is usually not permanent and the
disease usually progresses to macular atrophy after the anti-VEGF treatment [4,5].
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Age is a predominant risk factor contributing to the development of any AMD, with the prevalence
reaching nearly 30% over the age of 85 years in a European population [6]. Environmental factors,
such as diet (fat intake and antioxidants) and lifestyle, particularly smoking [7,8], also contribute to the
risk of developing the disease. There are several genetic variants that are associated with an increased
prevalence of AMD [9]. The two most significant of these are polymorphisms in the CFH and ARMS2
(age-related maculopathy susceptibility 2) genes. The CFH gene encodes for complement factor H,
a glycoprotein which has an integral role in the regulation of the alternative complement pathway [10].
The ARMS2 gene [11,12] encodes the ARMS2 protein, which helps to initiate complement activation
from the surface of retinal monocytes and microglia by binding to the surface of apoptotic and necrotic
cells [13]. More than 50 genetic variants at 34 loci have been associated with AMD development [9].
A large proportion of these genetic variants are located in or near genes of the complement system,
lipid metabolism, and extracellular remodeling [14]. These genetic associations, along with risk factors
related to diet, serum cholesterol, and triglyceride levels for late-stage AMD [15], highlight the potential
importance of studying metabolomic changes to identify systemic molecular biomarkers associated
with these risks. In addition, the cellular interactions and exchange of metabolites between the retina,
RPE, and choroid complex also provide an important basis of studying local metabolomic alterations in
AMD. Considering that the metabolome is closer to the molecular phenotype than either the genome,
the transcriptome, or the proteome [16], the study of metabolites could lead to better prediction of the
resulting phenotype than other -omics approaches. With AMD progression increasingly associated
with metabolic dysfunction, there is the potential for systemic and local metabolic biomarkers to
provide opportunities to detect and follow the progression of the disease at an early stage. Systemic
biomarkers and the role of lipid metabolism in AMD has been comprehensively highlighted [17,18],
whilst general reviews have briefly covered the metabolomics of AMD, alongside other ocular diseases,
and the limitations associated with such studies [19–21].
The aim of this review is to specifically highlight metabolic processes occurring within the retina,
including those related to the development of AMD. It will also provide an in-depth overview of
metabolomics studies conducted in AMD. The possible biofluids and metabolomics methods will
also be discussed, as well as the potential utility of metabolomics for discovering biomarkers and
identifying new therapeutic approaches for AMD and related diseases.
2. Metabolic Processes in the Posterior Eye
2.1. Energy Sources in the Retina
The complex cellular interactions in the retina give rise to a unique metabolic environment, which
is influenced by a range of external factors, including the differential blood supply to the layers of
the retina and the detection of light or darkness by the photoreceptors [22]. Due to the number of
cell types, there are various metabolic processes which occur throughout the vertebrate retina [23].
Glucose is the primary fuel source for the photoreceptors in the retina, supplied by the choriocapillaris
through the Bruch’s membrane (BrM) and the RPE. The metabolic environment of the retina is diverse
and increases in complexity with the laminated morphology present between the cells. For instance,
the glucose concentration decreases from the RPE surface to the retina surface in vitro [24,25]. Aerobic
glycolysis is the primary form of energy metabolism in the retina [26], where glucose is converted
to lactate at a comparable rate to cancer cells [27], even when there is plenty of oxygen. In avascular
retinas [28], an alternative energy source to adenosine triphosphate (ATP) is required as ATP is exposed
to highly active ATP degrading ion pumps between the centrally located photoreceptor mitochondria
and the photoreceptor synaptic terminal [29,30]. The phosphocreatine shuttle is instead used [30] and
although this is not essential in vascularized mouse retinas, an isoform of the creatine kinase is still
localized at the photoreceptor synaptic terminal. The energy metabolism of the retina is unique in that
it is dependent on the light or dark state of the tissue and respiration is more uncoupled from ATP
synthesis than in other tissues [31].
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RPE cells appear to be different from photoreceptors in that they are specialized to utilize reductive
carboxylation as a source of energy [32]. This minimizes RPE glucose consumption for the reduced
form of nicotinamide adenine dinucleotide phosphate (NADP(H)) generation, so efficient glucose
transport occurs between the choroid and retina. This process is disrupted by excessive oxidative stress
and mitochondrial dysfunction, which can be a result of an inability of mitochondria to access necessary
substrates, as well as defective electron transport and ATP-synthesis systems [33]. Glycolysis and
reductive carboxylation become hindered [32] as pyridine nucleotides, such as reduced nicotinamide
adenine dinucleotide (NAD(H)), are depleted, which leads to RPE and retinal degeneration [34,35].
When glycolysis is promoted in these cells, photoreceptors die [36,37], leading to the conclusion
that the retina and RPE contribute specific metabolic functions, which maintain their own functional
ecosystem [38], both in vivo and in vitro.
2.2. Lipofuscin Accumulation in the RPE
Lipofuscin is a lipid-containing, pigmented granule, which accumulates in various tissues
throughout the body as a result of aging, and can be found as an accumulation in the RPE [39].
Lipofuscin accumulation is a potential risk factor contributing to the development of AMD [40].
RPE cells convert the condensation product of all-trans-retinal and phosphatidylethanolamine to
N-retinyl-N-retinylidene ethanolamine (A2E), which is a major component, and the main chromophore,
of lipofuscin [41,42]. There is direct evidence that A2E alters cholesterol metabolism in the RPE,
contributing to AMD [43]. In addition, A2E directly causes RPE cytotoxicity by inducing apoptosis
through specific inhibition of cytochrome c oxidase (COX) [44,45], which leads to the inhibition of
oxygen consumption and light homeostasis. This increase in oxidative stress leads to mitochondrial
dysfunction, which releases two apoptosis-promoting molecules, cytochrome c and apoptosis inducing
factor (AIF) [46,47], from the mitochondria of RPE cells [45]. Lipofuscin could, therefore, contribute
to the disruption of mitochondrial function and oxidative stress in AMD. This is further highlighted
through links that lipofuscin has with the essential trace element, zinc, which is highly concentrated
in the RPE.
In the retina, zinc is required for the metabolism of ingested photoreceptor outer segments (POS)
by the RPE [48] and provides protection against oxidative stress [49]. For this reason, it has been
suggested that zinc deficiency is linked with AMD, with oral supplementation providing a protective
effect [50–52]. This decreases the risk of progression from intermediate stages of the disease to the
neovascular form in clinical trials [53], but the direct effects of zinc deficiency in the retina remain to
be explored extensively. Julien et al. [54] identified an accumulation of lipofuscin and lipofuscin-like
products in the RPE of zinc-deficient rats, which may contribute to AMD progression [40]. The authors
also proposed that this zinc deficiency contributed to lipofuscin accumulation due to the oxidative
stress and functional deficiency of RPE lysosomes as a result of lipid membrane damage caused by
lipid peroxidation from zinc deficiency [54]. This ultimately led to incomplete degradation of POS
in the dysfunctional RPE lysosomes [55]. This has been further demonstrated in more recent studies
exploring the mechanisms of zinc deficiency and supplementation [52,56].
There is also evidence which suggests that the link between lipofuscin accumulation in the RPE
and AMD progression is more tenuous. Although A2E is known to be produced in the RPE, it has been
shown that, in humans, A2E is preferentially located in the RPE cells of the peripheral retina, rather
than the central area of the retina containing the macula [57]. Therefore, in fundus autofluorescence
(FAF) imaging, the higher levels of lipofuscin fluorescence associated with the central area of the RPE
cannot be exclusively attributed to the concentration of A2E. Other studies have also contradicted
the aforementioned results of an increased signal on FAF by quantitatively determining that the
fluorescence signal associated with lipofuscin and A2E decreases from subgroups of early to late
AMD patients compared to controls [58,59]. As metabolic waste products, including lipofuscin, have
previously been associated with AMD progression, clinical trials began to investigate the treatment of
GA by limiting the metabolic waste accumulation within the RPE [60,61]. These studies showed no
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significant reduction in the rate of progression of GA, further highlighting the inconsistent evidence
regarding lipofuscin accumulation and its role in the development of AMD.
2.3. Sub-RPE Accumulations
2.3.1. Lipid Accumulation
The trafficking and accumulation of lipids and lipid metabolites have long been associated with
BrM aging [62–64]. As identification of these lipids has progressed, studies identified esterified and
unesterified cholesterol (EC and UC, respectively), which are also known as cholesteryl ester (CE) and
free cholesterol (FC), respectively [65,66]. Oil red O staining demonstrated that the EC accumulated
in the macula seven-fold more than in the periphery of the retina [64,67]. Although EC accumulates
exclusively at the BrM, UC and other phospholipids are also found within cellular and intracellular
membranes [68]. The association between cholesterol and lipids in the retina, their link to AMD,
and potential therapeutic target strategies have previously been reviewed [18,69,70] (Figure 1).
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formation of drusen. LCAT, lecithin-cholesterol acyltransferase; APOA1, apolipoprotein A1; CETP, 
cholesteryl ester transfer protein. Colored arrows represent lipid receptors and their direction of 
transport. Reproduced with permission from van Leeuwen et al. [18]. 
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Advanced glycation end products (AGEs), oxidized products of non-enzymatic, extracellular 
protein and lipid glycosylation, have been associated with and implicated in AMD progression for 
several decades. In one early investigation, the accumulation of these molecules was associated with 
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neovascularization associated with AMD, and more recently, they have been found to accumulate in 
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Figure 1. The metabolic flux of various lipids and their associated proteins in the retinal pigment
epithelium (RPE). In addition to anabolic and catabolic lipid metabolism, the RPE also functions as
a transfer site for lipids and proteins (yellow and green spheres) between the circulation and the
photoreceptors. The influx of lipids from the RPE to the photoreceptors is represented on the left
side, whilst the efflux of lipids is represented on the right side of the image. There is substantial
recycling of lipids by the RPE, which are continuously provided through the phagocytosed membrane
discs of photoreceptor outer segments (POS). The oxidized lipid species either enter the circulation
as lipoprotein particles (green spheres) or are basally deposited into the sub-RPE space leading to the
formation of drusen. LCAT, lecithin-cholesterol acyltransferase; APOA1, apolipoprotein A1; CETP,
cholesteryl ester transfer protein. Colored arrows represent lipid receptors and their direction of
transport. Reproduced with permission from van Leeuwen et al. [18].
2.3.2. Advanced Glycation End Product Accumulation
Advanced glycation end products (AGEs), oxidized products of non-enzymatic, extracellular
protein and lipid glycosylation, have been associated with and implicated in AMD progression for
several decades. In one early investigation, the accumulation of these molecules was associated
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with soft, macular drusen and RPE cells [71]. This accumulation was proposed to contribute to the
neovascularization associated with AMD, and more recently, they have been found to accumulate in
the BrM [72]. In this localized region, they inhibit protein function and are associated with age-related
damage. ARPE-19 cells have also been grown in the presence of AGEs, which leads to an additional
increase in the accumulation of lipofuscin, which has its own implication in the pathogenesis of AMD
previously discussed.
As these chemical modifications are promoted by smoking, a major risk factor for AMD
development [73], it is not surprising that AGEs and their receptors (RAGEs) are suggested to promote
the development of AMD. A more recent study investigated the activation of the AGE receptor (RAGE)
when the threshold for AGE accumulation is reached [74]. The activation of RAGE is associated with
transitioning an acute inflammatory response to a more chronic disease, as indicated in this study,
which demonstrated that RAGE was significantly associated with CNV in mice.
2.3.3. Drusen Accumulation and Development
One of the main issues surrounding the prevention of AMD is that the early stages of the
disease are often asymptomatic. This means that AMD is often identified when a patient has already
progressed to the intermediate stage of the disease and might be suffering from partial sight loss.
Early stage AMD can still be characterized by the presence of sub-RPE deposits, which accumulate
with age and are associated with the thickening of Bruch’s membrane. Sub-RPE deposits are focal,
termed drusen, or diffuse, termed basal laminar (BLamD) or linear (BLinD) deposits. Their formation
can contribute to RPE detachment and photoreceptor death [75–77]. Lipids, proteins, minerals, and
cellular debris are constituents of all sub-RPE deposits, but the composition of the various types can
differ [78]. Hard drusen are associated with the normal aging process while intermediate and large soft
drusen, as well as BLinD and BLamD, are implicated as contributing to increased disease susceptibility,
especially when they are present in the macula [79]. Using new clinical imaging modalities, sub-RPE
deposits are becoming better phenotyped in clinical settings [80] and, in combination with laboratory
imaging, can help to develop better diagnosis [81].
Although drusen form in the natural aging process, when they increase in number and size,
they are critical for the development of late-stage AMD. Indeed, an increase in drusen volume, as
measured with spectral domain optical coherence tomography (SD-OCT) in vivo, has been shown
to increase the risk of progression from the intermediate stages to advanced AMD [82,83]. Various
research groups have begun assessing the molecular constituents contributing to this pathological
accumulation. The molecular composition of drusen has been studied in the past, with a major focus on
the proteins present in drusen. Common components repeatedly found include apolipoprotein E [84];
amyloid components, including amyloid β [85,86]; complement components; and vitronectin [87,88].
Although the protein composition of sub-RPE deposits is not limited to these proteins, it is worth
noting that they were also found to be coating hydroxyapatite (HAP or Ca5(PO4)3OH) spherules [89]
and large HAP nodules [81]. These studies suggest that metabolic changes associated with mineral
formation are involved. It has been shown that HAP can be deposited onto cholesterol-containing
extracellular lipid droplets, after which proteins can bind and oligomerize to start forming the sub-RPE
deposits (Figure 2). This HAP deposition and subsequent loss of permeability of the BrM can be
modelled in primary cell culture [90], therefore, the metabolic changes associated with mineralization
can now be explored.
2.3.4. Trace Metal Homeostasis
Altered metal ion homeostasis has also been implicated in AMD. Apart from zinc and calcium,
which were discussed in Section 2.2. and Section 2.3.3., respectively, another metal ion commonly
implicated in AMD is iron.
Iron is well known to contribute to retinal degeneration [91], where it causes damage through the
induction of oxidative stress. Within the RPE, the accumulation of iron contributes to the buildup of
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lipofuscin [92]. In the sub-RPE space, iron accumulation can interfere with molecular pathways, such
as the complement system [93].
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en t e metal ion content of sub-RPE deposits were determined in the macula, equator, and far
periphery of the retina [94], iron appeared to have the lowest concentration when compare to zinc or
calcium, regardless of the geographical locations.
While the underlying mechanisms for the positive effects of zinc are ot yet fully understood,
recent evidence suggests that there are multiple effects on the RPE of externally a ded zinc [52].
However, uncontrolled regulation of zinc levels can have negative effects at both ends of the spectrum.
Zinc deficie cy appears to be linked to lipofuscin accumulatio in RPE cells [54] and it has been
shown to impair the phagocytic and lysosom l activity of RPE cells through lipi peroxidation [56].
Alternatively, an excess of zinc contributes to RPE cytotoxicity [95] and can lead to zinc deposition,
notably in the sub-RPE space [96]. There is also evidence suggesting that zinc is involved in the
oligome ization of CFH and the modulation of the complement cascade and contributes to the protein
content of sub-RPE deposits [93].
2.4. Choroid-BrM-RPE Interaction
The choroid is the vascularized layer of the eye, which is located between the retina and the sclera,
with the innermost layer (choriocapillaris) located on the basal side of the BrM. The retina of humans
and other non-human primates is supported by the underlying choroidal vasculature and the retinal
vasculature, which supports the inner retina. These dense capillaries are fenestrated on the retinal
surface to supply oxygen and nutrients to the RPE and photoreceptors, as well as removing waste
products generated in these highly metabolic cells. Studies on the blood flow of the choroid have
been carried out [97], where it has previously been determined that a small portion of the choroidal
blood flow reaches the retinal photoreceptors. This is primarily due to the high blood flow relative to
the small tissue mass [98,99], which exists to account for the poor (< 1 volume %) oxygen extraction
from the blood to supply the outer retinal structures [100,101]. The high metabolic demands of the
photoreceptor inner segments means that, under normal conditions, there is a large oxygen supply
from the choroid to help overcome the issue of distance [102]. This causes an issue when there is any
disruption to the distance between the choroid and photoreceptors (such as in the presence of sub-RPE
drusen), as the lack of oxygen will lead to progressive photoreceptor degeneration. Chirco et al. [103]
have recently reviewed the changes that occur to the choroid with aging, at both a structural and
molecular level, and how this relates to AMD disease progression.
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The blood-retinal barrier formed by the tight junctions of the RPE is important for the supply of
nutrients to the photoreceptors. The BrM was first thought to form part of this barrier, but it became
apparent in early studies that it was relatively permeable compared to the RPE and, instead, was more
important in the removal of waste products from the retina. Unfortunately, as the BrM thickens with
age, it becomes increasingly impermeable to the low concentrations of waste products that begin
to accumulate in the sub-RPE space. The opposite has been found to be the case for the choroid,
which appears to thin with age, particularly at the fovea [104]. This effect happens alongside a decrease
in von Willebrand factor and human leukocyte antigen (HLA) class I proteins [105], both vascular
specific proteins. This suggests that there is a dedifferentiation of the endothelial cells in eyes with
early AMD and, along with the loss of the RPE cell layer, provides an insight into the steady metabolic
dysregulation associated with the development of AMD.
3. Metabolomics in AMD
3.1. Introduction into Metabolomics
Metabolomics can be defined as the measurement of all small molecule metabolites within
a biological system [106], including those that are environmental in origin. There is an increasing
understanding of the components associated with the transcriptome and proteome, but the metabolome
offers an integrated perspective of cellular processes and the effect environmental factors may have
on the biological state (Figure 3). Compared with the other ‘-omics’ approaches for investigating
changes in the physiology of individuals and populations [107], metabolomics remains in its infancy.
However, its popularity has rapidly increased over the last two decades. Mass spectrometry (MS)
and nuclear magnetic resonance (NMR) spectroscopy are the predominant platforms that are used
to obtain metabolomic profiles from a diverse range of sample types. To increase its resolution
and sensitivity, MS is combined with different separation techniques, such as gas chromatography
(GC) and high-performance liquid chromatography (HPLC) [108]. NMR spectroscopy is useful for
metabolomic investigations because of its reliability and for the structural information it provides.
NMR is not as sensitive as MS, making it more useful for quantifying high abundance metabolites.
Furthermore, NMR does not always offer the high-throughput data acquisition that is common with
mass spectrometers. However, there is evidence that this barrier is now being overcome [109].
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Figure 3. Overview of the various omics approaches that can be applied to assess the biological
components that contribute to multifactorial diseases, such as age-related macular degeneration
(AMD). Metabolomics is highlighted in green a n approach to test the effect of the environment
and processes in the body on the development of disease. Microbiomics is growing in importance
in understanding disease, but how it influences the whole system in a human, or in fact in animals,
is yet to be determined. Adapted from Lauwen et al. [110].
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Sample preparation is critically important in metabolomic investigations because metabolites
could be introduced, altered, or removed during processing, which may not reflect the actual molecular
state of an organism. For this reason, there is a preference for the use of biofluid samples over
tissues or cells for some applications because they require less processing [111–113]. As the biofluids
are in contact with various organs throughout the body, they also provide a more representative
global metabolic profile. Even with the best sample preparation, there are still limitations as the
current techniques of subsequent separation and detection methods are unable to identify all in vivo
metabolites, primarily due to the heterogeneous and diverse chemistry of the currently known
metabolites [114,115]. As these separation and detection platforms improve, there will be increasing
numbers of studies investigating greater depths of metabolomics knowledge and understanding,
as already evidenced by the rapid expansion of identified human metabolites from just over 6,800 to
over 110,000 metabolite entities [116,117].
3.2. Retinal Tissues
In AMD, metabolomics studies have been conducted using samples obtained from animal models
and human patients. A summary of untargeted cellular, human, and animal AMD metabolomics
studies and the specific techniques used can be found in Table 1. One such study explored the
metabolic changes associated with photoreceptor degeneration, a consequence of late stage AMD
and GA, as well as whether induced pluripotent stem cell (iPSC)-generated RPE cell grafts altered
this metabolomic profile [118]. The metabolites from rat eyes at different time points post-graft were
processed by HPLC-QTOF-MS (quadrupole time-of-flight mass spectrometry) and were analyzed
against the METLIN database. When comparing 52-week old dystrophic rats against age-matched
control rats, significant changes were reportedly observed at 3 weeks, with most changes occurring
at 52 weeks. Of the 203 metabolites which significantly changed in the diseased samples, more
than half were phospholipids and various oxidized species. Glycerophosphocholines were the most
abundant subclass that changed, followed by glycerophosphoethanolamines, long-chain acylcarnitines,
monoglycerols, fatty acid amides, and long-chain polyunsaturated fatty acids (LC-PUFAs). There was
a general increase in the fold-change of phospholipids in the dystrophic tissue, suggesting a higher
level of lipid metabolism in the diseased eyes. Alternatively, there appeared to be a downregulation
of the acylcarnitines, which are important for energy homeostasis and RPE function, and of the
docosahexaenoic acid ω-3 fatty acid (DHA), which is necessary for retinal homeostasis [119,120].
DHA is the precursor of various phospholipids found enriched in the outer segment membranes
of the retina, including lysophosphatidylcholine (lysoPC), lysophosphatidylethanolamine (lysoPE),
and lysophosphatidylserine (lysoPS), all of which were downregulated in a similar manner as DHA.
A similar decrease was observed over time for all-trans-retinal (atRAL) in Royal College of
Surgeons (RCS) rats, which is indicative of photoreceptor degeneration [121], along with an increase
in the toxic A2E fluorophore. This resulted from inefficient clearance of atRAL in the dysregulated
visual cycle [122]. The final part of their study identified that stem cell-derived RPE rescued the loss
of DHA-lipids associated with the diseased phenotype, suggesting RPE transplantation could be
a metabolic mediator with therapeutic benefits [123].
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Table 1. Summary of untargeted metabolomic studies investigating AMD, including details of the tissue/biofluid profiled, and methods and instrumentation used.
Subjects and Biofluid Used Number of IdentifiedMetabolites Metabolite Separation Method (Chromatography) Detection Instrument Used Reference
Mouse eye lysates Not reported Imtakt Scherzo SM-18 150 × 2 mm columnAgilent 1200 capillary LC Agilent 6538 UHD-QTOF MS (ESI+/ESI-) [36]
Mouse eye lysates 203 XBridge C18 column (3.5 µm, 135 Å, 150 mm × 1.0 mm)
Agilent 1260 HPLC
Agilent 6538 UHD Accurate Mass Q-TOF (ESI+) [118]
Human serum (NVAMD);
Mouse eye lysates Not reported
Aeris Peptide XB-C18 column (3.6 µm, 100 × 2.10 mm)
Phenomenex HPLC
Untargeted: Thermo Scientific LTQ Velos Orbitrap
(ESI+/ESI-)
Targeted: Thermo Scientific LXQ (ESI-)
[124]
hfRPE cells; Mouse retina;
Apical/basal secretomes
202
(101 in medium; 53 changed
substantially)
Ethylene bridged hybrid Amid
column (1.7 µm, 2.1 mm × 150 mm)
Agilent 1260 HPLC
AB Sciex QTrap 5500 (MRM) [125]
Human plasma (NVAMD) 1168 (94 differed significantly) Hamilton PRPX-110S (2.1 cm × 10 cm) anion exchangecolumn Thermo LTQ-FT spectrometer (ESI+) [126]
Human plasma (NVAMD) 864 (10 differed significantly) Acquity HSS T3 UPLC column (1.8 µm, 2.1 × 100 mm)Agilent 1290 Infinity UHPLC AB SCIEX Triple 6600 TOF (ESI+/ESI-) [127]
Human plasma 1188 spectra(30 low-Mw metabolites)
N/A
NMR: Bruker Avance DRX 500 spectrometer
(300 K) operating at 500.13 MHz for protein, with a
5 mm TXI probe
[128]
Human plasma (nonexudative) 698 endogenous (87 associatedwith AMD)
C18 (acidic positive and basic negative ionization);
HILIC (negative ionization)
Waters ACQUITY ultra-UPLC (Metabolon, Inc.)
Thermo Scientific Q-Exactive (HESI-II), Orbitrap
mass analyzer [129]
WT mouse plasma (MS) and
urine (NMR)
MS: 309
NMR: 47
Polar and nonpolar lipids: ACQUITY BEH C8 column
(1.7 µm, 100 × 2.1 mm)
Simadzu Nexera X2 UHPLC
Hydrophilic metabolites: Atlantis HILIC column
(3 µm, 150 × 2 mm)
Shimadzu Nexera X2 UHPLC
Additional polar metabolites: Phenomenex Luna NH2
column (150 × 2.0 mm)
ACQUITY UHPLC
Polar and nonpolar lipids: Thermo Scientific
Exactive Plus Orbitrap MS (ESI+)
Hydrophilic metabolites: Thermo Fisher Scientific
Q Exactive hybrid quadrupole Orbitrap MS (ESI+)
Additional polar metabolites: AB SCIEX 5500
QTRAP MS (ESI- and MRM)
NMR: Bruker Avance 600 spectrometer
[130]
Human plasma (NVAMD) 159 features differed (39 withmedium to high confidence)
Hamilton PRP-X110S, 2.1 × 10 cm (anion exhchange) a
Higgins Analytical C18 column, 2.1 × 10 cm
(reverse phase) a
Thermo Scientific LTQ Velos Orbitrap MS (ESI+) [131]
a Chromatography methods not stated, therefore, the above description was obtained from references provided in the study text.
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Comparable results have been obtained when using mouse models of photoreceptor degeneration
to compare healthy mice and AMD patients. Orban et al. [124] used tandem MS to analyze the
Abca4-/- Rdh8-/- mice, which exhibit retinal degeneration under light-induced photoreceptor damage.
This revealed that 11-cis-retinal and DHA levels were both decreased, whilst intense light produced
increased levels of prostaglandin G2. The animal model metabolite differences also appeared in serum
from AMD patients suffering from the nonexudative form of the disease in the dysregulation of DHA.
Intense light also reduced the levels of DHA in wild-type mice, but this did not lead to photoreceptor
degeneration. One of the differences between the disease seen in mice and the AMD patients was the
statistically significant increase in arachidonic acid (AA) in the human serum, which was not present
in the mice eyes. This study also employed a statistical model as a predictive tool for the identification
of AMD, which gave a 74% chance of identifying AMD patients when compared to controls using
only DHA and AA. The inclusion of the AMD-associated Ala69-Ser variant in the ARMS2 gene did
not significantly improve this model. This was primarily because only a small correlation was found
between the genetic mutation and AMD, meaning that, in these samples, the genetic screen for this
amino acid transition was not a good predictor of AMD development. This variant has previously
been shown to be associated with AMD progression and could be used as a predictive tool [11],
which indicates using multiple models with independent biomarkers are a better diagnostic strategy
to employ.
As it is well documented that the environment can impact the metabolome, it may also be worth
noting how different tissue collection methods are employed for metabolomics studies. One study
has highlighted the potential impact of anesthesia and euthanasia on metabolomics studies carried
out on tissues [132]. Here, it is highlighted that there are tissue-specific changes dependent on the
method of tissue sampling. For example, after euthanasia, skeletal muscles showed higher levels of
glucose-6-phosphate, whereas nucleotide and purine derived metabolites accumulated in the heart
and liver, when compared to anesthetized animal tissues. Although the authors recommend utilizing
anesthesia for tissue collection, this may not be feasible for every study and, instead, highlights a point
of consideration in tissue metabolomics studies.
Another consideration for metabolomics studies is post mortem time, especially in humans.
There is evidence from GC-MS and ultra-high performance LC-MS (UHPLC-MS) studies in the eye
that statistically significant post-mortem changes can be observed in a number of metabolites, although
most metabolites were stable for up to eight hours post-mortem [133].
3.3. RPE Cells
Although several cellular models have been developed to replicate the RPE layer in vivo,
the complex cellular environment of the retina means the exact environment is difficult to mimic.
The human fetal RPE (hfRPE) cellular model is possibly the most reliable model of RPE cell function
as it appears to replicate the physiological RPE morphology that other cell models and cell lines
do not [134–136]. The use of this cell model as an accurate indicator of cellular metabolism may
be helpful for metabolomics investigations [137]. The retina contains many different cell types,
which have preferential metabolic pathways for energy metabolism, such as aerobic glycolysis
in photoreceptors and reductive carboxylation in the RPE. In addition to the metabolism studies
mentioned previously [23,125,138], these primary cell culture models also provide a platform for
studying the development of drusen deposits in vivo [139], which are important factors in the
development of GA. This has been expanded upon in recent years, with the identification of individual
components of the drusen already mentioned [78,89,90]. Of interest is the accumulation of HAP, which
is not commonly found in healthy soft tissues. The accumulation of high concentrations of phosphate
and calcium, together with other divalent ions, in the sub-RPE space provided a new insight into
the development and progression of sub-RPE deposits. It is perhaps unsurprising that there is an
accumulation of phosphate and calcium, given that the retina is one of the most metabolically active
tissues in the body [140–142], and the RPE has a very high calcium content [143]. Sphingolipids
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are one metabolite class that have been demonstrated to both contribute to, and protect against,
photoreceptor apoptosis [144–146], as well as potentially having a role in choroidal and retinal
neovascularization [147,148]. Another role that could be related to the deposition of calcium-phosphate
at the RPE basement membrane is the role sphingolipids and their potential kinases have in calcium
mobilization, particularly in response to the influx of calcium via transient receptor potential (TRP)
channels [146,149–151].
Each of the cell types within the retina must communicate with one another to maintain a regular
homeostatic environment and function properly to maintain viability. Recently, Chao et al. [125]
investigated the consumption of nutrients and the subsequent transport of metabolites through the
RPE cell layer. Through LC-MS/MS, 120 metabolites were identified in the culture medium of hfRPE
cells and three were identified as being the most heavily consumed nutrients. Glucose and taurine
showed the highest consumption from the apical medium, with proline consumed from both the apical
and basal medium after 24 hours. Through isotopic labelling, they were also able to identify that
metabolic intermediates from both glucose and proline metabolism were preferentially exported to the
apical side of the culture, which is then imported into the neural retina when co-cultured. Proline is
an energy source, which is utilized by both the citric acid cycle and the reductive carboxylation pathway.
This provides a valuable insight into the unique metabolism that may occur in vivo, demonstrating the
use of alternative metabolic pathways in RPE cells and indicating metabolite secretions, which may
present as biomarkers that could change when the RPE is in a diseased state. This publication further
proved human primary RPE cells are suitable model systems to study the dynamic changes in and
around the RPE [125]. Further manipulation of culture conditions will now be able to study differences
in the metabolism, which could mimic those found at the photoreceptor/RPE/choroid interface.
3.4. RPE Cells and the Retina
The metabolic connection between RPE cells and photoreceptors means that the loss of the RPE
cell layer is detrimental, not only to the choriocapillaris, but also as a contribution to photoreceptor
degeneration in the late stages of AMD [152–155]. Knowing that the RPE cells provide a homeostatic
platform for the underlying photoreceptors, and that their degeneration contributes to the pathogenesis
of AMD, Kurihara et al. [36] investigated the effects of oxidative stress on this cellular interaction as
an early indicator of the disease. Using a murine model and primary RPE cells cultured from mice,
the authors found that a hypoxic environment, induced from choriocapillaris vasodilation, led to the
accumulation of lipid molecules, BrM thickening, RPE hypertrophy, and significant photoreceptor
degeneration [36]. In addition to the pathological changes associated in the different cell types,
glucose metabolism also became impaired within the hypoxic RPE. This was evidenced by the shift
from oxidative phosphorylation to glycolytic metabolic pathways, under hypoxic environments,
in vivo. This was supported by increased apical RPE uptake of glucose in vitro, which subsequently
reduced available glucose for photoreceptor metabolism. These results are similar to those suggested
in other studies looking directly at the effects of RPE and photoreceptor metabolism [125,138]. Through
untargeted MS analysis, it was revealed that various forms of acylcarnitines were also significantly
different in the von Hippel Lindau (Vhl) knock-out mice [36]. When combined with the gene knockout
for hypoxia-inducible transcription factor 2 (HIF2α), the levels of acylcarnitines were of a similar
level to that in control mice. This is similar to results obtained in other animal models using the
same two genetic mutations [156,157], which suggests that HIF2α could play a crucial role in retinal
lipid regulation as the combined genetic knockout of Vhl/Hif2α partially restores the wild-type lipid
homeostasis. This is just one example that investigated the effects of oxidative stress on the RPE,
but the overall literature in oxidative stress and the RPE were recently reviewed in the context of
neovascular AMD (NVAMD) [158].
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3.5. Biofluids
One of the first investigations into the metabolic changes associated with oxidative stress in AMD
was performed in blood, but later studies on different biofluid metabolites were also investigated.
These are summarized in Table 2. In the first study, the authors targeted metabolites, which were
products of thiol redox reactions and lipid peroxidation [159]. Blood plasma samples from AMD
patients and control individuals were assessed for cysteine (Cys), cystine (CySS), glutathione (GSH),
isofurans (IsoFs), and F2-isoprostanes (F2-IsoPs), chosen based on previous results demonstrating that
increased oxidation of these metabolites were associated with AMD risk factors [160–162]. Using HPLC
and gas chromatography MS (GC-MS), they identified that only the levels of CySS were significantly
higher (9.1%) when comparing AMD patients and controls. The levels of CySS were also significantly
greater between neovascular and advanced AMD patients compared to controls. However, when the
analysis was adjusted for age, gender, and smoking, the results were no longer significant and so the
results are only suggestive of possible systemic metabolite changes.
An additional group used a targeted approach to investigate the association of long-chainω-3
PUFAs, triglycerides, and high (HDL) and low (LDL) density lipoprotein-cholesterols in patients with
NVAMD [163]. Serum and red blood cell membrane (RBCM) fatty acids were determined by GC,
whereas enzymatic colorimetric and electrophoretic methods were employed to measure triglycerides
and the serum lipoprotein-cholesterols. Compared to control samples from individuals with no
history of ocular diseases, the NVAMD patients had significantly lower plasma triglycerides, serum
eicosapentaenoic acid (EPA), RBCM EPA, and DHA after adjustment for age and sex. Similar levels of
plasma total, HDL-, and LDL-cholesterol, as well as serum DHA and EPA+DHA (omega-3 index), were
observed in both NVAMD patients and the controls. These results build on a previous population-based
study by the same group [164], which showed a trend of a decreased risk to progress to NVAMD in
patients with higher plasmaω-3 LC-PUFAs. A decrease was also found between the plasma EPA in
the Alienor study [164], which was not associated with AMD, as opposed to the significant association
of AMD with serum EPA in the more recent study [163]. Decreased levels of DHA in association with
AMD has previously been highlighted in Section 3.2. [118,124].
The same group that investigated oxidative stress in AMD patients [159] progressed to
an untargeted metabolomic investigation of plasma in NVAMD patients and age-matched controls with
no clinical signs of AMD [126]. Using LC-FTMS (Fourier-transform mass spectrometry), there appeared
to be significant changes in the intensity of 94 metabolites between the two cohorts. A more
detailed analysis revealed a total of 40 metabolites that overlapped between the log2 transformed
and non-transformed data. Cluster analysis of these 40 metabolites showed significant increases
in certain peptides, modified amino acids, and natural products, defined as either a metabolite
synthesized by a living organism or a metabolite specifically involved in secondary or specialized
metabolism [165]. Significant decreases were found in bile acids, vitamin D-related metabolites,
and dipeptides (histidine-arginine and tryptophan-phenylalanine) in NVAMD patients compared to
controls. Pathway analysis of these metabolites revealed that phenylalanine and dopaquinone in the
tyrosine metabolism pathway, which aids in the synthesis of melanin [166], or aspartate and glutamine
in the urea cycle pathway, a natural process to remove excess nitrogen from the body, are involved.
Metabolites 2019, 9, 4 13 of 36
Table 2. Metabolites in human biofluids differing between AMD patients and control individuals. The number of individuals assessed in each study is indicated
in parentheses.
Reference Biofluid Comparison MetabolomicTechnique Employed Definitively Identified Metabolites
Level in AMD Cohort
Compared to Controls
[124] Blood serum
NVAMD patients (n = 22) and
age-matched control patients
(n = 22)
LC-MS
Docosahexaenoic acid Lower
Amino acids Higher
Prostaglandin G2 Higher NS
[159] Blood plasma
Intermediate AMD (drusen),
late AMD (GA and CNV)
(n = 77) and non-AMD
control patients (n = 75)
HPLC and
GC-negative-ion
chemical ionization
(NICI)-MS
Cystine
Isofurans Higher
NS
[126] Blood plasma
NVAMD patients (n = 26) and
age-matched control patients
(n = 19)
LC- Fourier transform
MS (FTMS)
Acetylphenylalanine
Higher
Dipeptide; Tripeptides (modified cysteine and alanine a)
Sethoxydim
Tripeptides b
Tripeptides (acetyltryptophana)
Flavones; halofenozide
Glycocholic acid
Lower
Vitamin D-related metabolites; phytochemicals b
Glycodeoxycholic acid+H+;
Glycoursodeoxycholic acid+H+
Glycodeoxycholic acid+Na+;
Glycoursodeoxycholic acid+Na+
Sencrassidol
Didemethylsimmondsin
Dipeptides b
[127] Blood plasma
NVAMD patients (n = 20) and
age-matched control patients
(n = 20)
UPLC-TOF-MS
N-Acetyl-L-alanine
Higher
L-Tyrosine
L-Phenylalanine
L-Methionine
L-Arginine
Isomaltose
N1-Methyl-2-pyridone-5-carboxamide
Lower
L-Palmitoylcarnitine
Hydrocortisone
Biliverdin
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Table 2. Cont.
Reference Biofluid Comparison MetabolomicTechnique Employed Definitively Identified Metabolites
Level in AMD Cohort
Compared to Controls
[167] Blood serum
NVAMD patients (n = 20),
PCV patients (n = 20), and
age-matched controls (n = 20)
UPLC-QTOF-MS
Glycerophospholipids c
Higher
Phosphatidylcholine
Covalently modified amino acids c
Di/tri-peptides c
Tripeptides c
ω-3 andω-6 PUFAs c
Pinolenic acid
Docoxahexaenoic acid
Eicosatetraenoic acid
Carnitine sp. c
[129] Blood plasma
AMD patients (n = 314) and
age-matched controls (n = 82),
both across two locations
HILIC- and UPLC-MS
Creatine d Higher
Oleic acid d
Higher fN(CH3)3 choline HDL
d
Acetate d
Dimethylsulfone d
Pyruvate d
Higher gGlutamine
e
Unsaturated F.A. e
Unsaturated F.A. LDL + VLDL e
Unsaturated F.A. d
Lower fUnsaturated F.A. LDL + VLDL d
Histidine d
Lower hAcetoacetate d
β-hydroxybutyrate d
Unsaturated F.A. LDL + VLDL e Lower f
Glutamine e
Lower g
Histidine e
CH2CH2COOR F.A. e
CH2CH2C=C F.A. e
Albumin lysil e
Alanine e
Lower hHistidine e
Glyceryl C1,3H’ e
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Table 2. Cont.
Reference Biofluid Comparison MetabolomicTechnique Employed Definitively Identified Metabolites
Level in AMD Cohort
Compared to Controls
[128] Blood plasma
AMD patients (n = 89) and
age-matched control patients
(n = 30)
NMR
N2-methylguanosine Higher
1-Stearoyl-2-oleoyl GPC Lower NS
1-Linoleoyl-2-arachidonoyl GPC
Lower
Stearoyl-arachidonoyl glycerol
Oleoyl-olyeol-glycerol
Dihomo-linolenoyl carnitine
1-Stearoyl-2-arachidonoyl GPC
Linoleoyl-linolenoyl glycerol
1-Stearoyl-2-linoleoyl-GPI f
Oleoyl-linoleoyl-glycerol
Oleoylcarnitine
Ximenoylcarnitine
1-Stearoyl-2-arachidonoyl GPI i
[131] Blood plasma
NVAMD patients (n = 100)
and control patients (n = 192)
LC-MS and
LC-MS/MS
L-Oxalylalbizziine j
Higher
Isopentyl beta-D-glucoside j
LysoPC(P-18:0) j
LysoPC(P-18:1(9Z)) j
LysoPC(16:1(9Z)) j
Darunavir j
Bepridil j
912-Hexadecadienoylcarnitine j
456-Trimethylscutellarein 7-glucoside j
1-Lyso-2-arachidonoyl-phosphidate j
Americanin B j
Corchoroside A j
N-Ornithyl-L-taurine j
Lyciumoside III j
LowerPhosphatidylethanolamine
f,j
Phytosphingosine j
Lenticin j
9-Hexadecenoylcarnitine k
Higher
Heptadecanoyl carnitine k
11Z-Octadecenylcarnitine k
L-Palmitoylcarnitine k
Stearoylcarnitine k
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Table 2. Cont.
Reference Biofluid Comparison MetabolomicTechnique Employed Definitively Identified Metabolites
Level in AMD Cohort
Compared to Controls
[168,169] Blood serum and
urine
Neovascular and
nonexudative AMD patients
(n = 104) l
NMR
Arginine Higher m,NS
Glucose
Lower m,NS
Lactate
Glutamine
Reduced glutathione
a When no specific metabolites were given (e.g., dipeptides), correlated Metlin matches with the same m/z are given; b No correlated Metlin matches; c Full list of 197 differing
metabolites can be found in Supplementary Table 1 of [167]; d Metabolites obtained from the Coimbra cohort studied; e Metabolites obtained from the Boston cohort studied; f Effect size
difference between early AMD patients vs controls; g Effect size difference between intermediate and early AMD patients; h Effect size difference between late and intermediate AMD
patients; i No metabolite identity given; j Metabolites identified through high-resolution LC-MS; k Metabolite identity confirmed through high-resolution LC-MS/MS; l Specific patient
cohort information not available; m When comparing NVAMD patients to nonexudative AMD patients. Abbreviations: AMD = age-related macular degeneration; F.A. = fatty acids;
GA = geographic atrophy; GPC = glycerol-3-phosphocholine; GPI = glycosylphosphatidylinositol (assumed, no definition given); HDL = high-density lipoproteins; LC-MS = liquid
chromatography-mass spectrometry; LDL = low-density lipoproteins; NVAMD = neovascular AMD; VLDL = very low-density lipoproteins; NS = not significant.
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Similarly, Luo et al. [127] assessed the plasma metabolomics profile of a Chinese cohort of patients
suffering from NVAMD and healthy controls using UHPLC-QTOF MS. In this study, there were
10 metabolites that differed significantly between the two groups, the majority of which were amino
acids, and the most significant finding was an increase in L-phenylalanine in AMD patients. A further
analysis of the associated metabolic pathways revealed that most metabolites belonged to the amino
acid biosynthesis pathway. The most common metabolites found across the metabolic pathways had
also been previously shown as having a significant change by Osborn and colleagues [126].
Untargeted metabolomic studies assessing metabolic differences between healthy individuals
and AMD patients are increasing in frequency. One such study used LC-MS/MS analysis to assess the
blood serum of 60 individuals characterized as either healthy controls, patients suffering with CNV,
or patients suffering with polypoidal choroidal vasculopathy (PCV) [167], a subtype of AMD commonly
found in Asian populations [170]. It was shown that glycerophospholipids, amino acids, di/tripeptides,
ω-3 and -6 PUFAs, and various carnitine species were all elevated in both CNV and PCV patient
samples. In total, there were 197 significantly altered metabolites across both conditions compared
to serum metabolites from controls. Only one metabolite (pinolenic acid) was shown to be different
between CNV and PCV patients, which suggests there could be significant metabolic overlap between
these two diseases [170]. The results from this study provided additional knowledge to previous
research, which compared the serum lipid profiles of PCV patients and compared these to controls [171].
A total of 41 metabolites were significantly altered in PCV patients, which included increases in
18 phosphatidylcholines (PCs), eight sphingomyelins (SMs), three lysoPCs, three platelet-activating
factors (PAFs), one lysophosphatidic acid (LPAs), and one phytosphingosine. Significant decreases
were found in one PC, three LPAs, two sphingosines, and one phosphatidylethanolamine (PE) [171].
The results from the PCV and AMD comparison study [170] were expanded in 2017,
where investigations into the plasma metabolomics profiles of AMD patients and healthy age-matched
controls were conducted using NMR [128] and UPLC-MS analysis [129]. For the plasma samples
analyzed by NMR, two large cohorts of AMD patients were recruited at two separate study locations
(Coimbra and Boston) and were characterized by the severity of their AMD progression. These were
compared against each other, as well as being compared against control samples from both study
cohorts. There were noticeable differences in the metabolic profiles between AMD severity stages,
including between samples from early-stage AMD and the control groups. There were higher levels
of circulating creatine, acetate, dimethyl sulfone, C18 cholesterol, and high-density lipoprotein
(HDL)-choline, whilst there were lower levels of unsaturated fatty acids between controls and the
early AMD Coimbra cohort [128]. Across the AMD severity stages, there were minor differences in
low-molecular weight (Mw) metabolites, such as higher pyruvate for intermediate AMD and lower
levels of histidine, acetoacetate, and β-hydroxybutyrate for late AMD. Samples from the Boston cohort
showed slight differences in the low-Mw- metabolites, with higher and lower levels of glutamine for
early and intermediate AMD, respectively. Lower histidine levels were found in intermediate and
late AMD, with lower levels of alanine in late AMD. As evidenced by the metabolites found between
the two different cohorts, there appears to be a geographic influence on the metabolites that present
as significantly different in AMD patients, again highlighting the influence of the environment on
metabolomics studies and disease profile.
A subsequent study by the same group analyzed plasma metabolites from patients with different
stages of AMD progression and age-matched controls, using UHPLC-MS [129]. Here, 87 metabolites
were identified as differing between AMD and controls. Most of the metabolites were members of the
lipid super-pathway (82.8%), followed by amino acids (5.7%). Similarly, six out of seven of the most
significantly different metabolites were lipids, the exception being adenosine. In terms of increasing
AMD severity groups, 48 metabolites significantly differed and all but one of the most significant
metabolites were involved in lipid pathways. Pathway analysis demonstrated that most were involved
in glycerophospholipid metabolism. It is important to note that Osborn et al. [126] were unable to
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distinguish the lipids that were present in their samples and so they were not analyzed and cannot be
compared to the study by Laíns et al [129].
Recently, the limitations of the original paper by Osborn et al. [126] have been improved on in
a study, which investigated the metabolites and associated metabolic pathways of a larger cohort of
NVAMD patients [131]. Plasma samples were collected from NVAMD patients, who exhibited extensive
CNV, subretinal hemorrhaging or fibrosis, or photocoagulation scarring in one or both eyes. Control
individuals were identified as having fewer than 10 small drusen and no macular pigment changes in
both eyes. Untargeted metabolomics was carried out using LC-MS, which identified 10,917 unique
metabolite features. Analysis of these features highlighted 159 metabolites that were distinguishable
between NVAMD patients and controls. There was an increase in 110 of these metabolites in
NVAMD patients, with 49 showing decreased levels, compared to controls. Further analysis identified
39 metabolites with medium to high confidence. Only metabolites that have been exclusively
identified have been listed in Table 2. Acylcarnities, amino acids, bile acids, lysophospholipids, and
phospholipids were amongst those annotated and, following Bonferroni-corrected pathway analysis,
the carnitine shuttle pathway was revealed to be significantly altered in NVAMD patients. Further
LC-MS/MS analysis confirmed the identity of five of the six carnitine shuttle pathway metabolites,
which all showed a significant increase in NVAMD patients. This larger cohort study builds on previous
NVAMD metabolomics research, which have also identified acylcarnitine and bile acid alterations in
the patient population [126,127].
Preliminary studies published as abstracts on metabolite profiles in AMD have also been compared
using NMR metabolite profiles of laser-induced mouse models of NVAMD and human AMD patients,
identifying lactate as an important metabolite in both cases [172,173]. Preliminary studies in urine
have also been carried out [168,169]. Here, the NMR profiles for NVAMD cluster well, whereas the
clustering of the nonexudative AMD patients was more diffuse. This may suggest a more heterogeneous
population and highlights differences between AMD subgroups. In NVAMD patients, there were
notable increases in arginine and decreases in glucose, lactate, glutamine, and glutathione. Results
obtained in urine showed an overlap between neovascular and nonexudative AMD, suggesting that
the two forms of the disease could be linked [168,169]. The metabolomics profile of subretinal fluid
has also recently been investigated [174], in the context of other ocular diseases, with 651 metabolites
identified in a small sample size of three patients.
It is perhaps not surprising that lipids are the most consistent metabolites that show changes
in the different stages of AMD. The role that lipids play in the pathogenesis of AMD is becoming
clearer though it is still to be fully elucidated [175]. The most significantly associated metabolites
in these studies belonged to the glycerophospholipid family, which provide structural stability and
fluidity to neural membranes. The most likely source of these are the degrading cell membranes
and photoreceptor outer segments’ discs. Although these studies provide a basis for the identity of
potential metabolic biomarkers present in the circulation and tissues of AMD patients and models of
AMD disease states, they may not be directly relatable to the process occurring in the retina.
4. Alternative Approaches for AMD Metabolomics Studies
4.1. Tears
Tears are a biofluid originating from the anterior of the eye and are a potential source of metabolite
biomarkers directly linked to ophthalmology. Although relatively small in volume [176], technological
advancements now make it possible to characterize the proteomic [177,178], lipidomic [179],
and metabolomic [180] composition of the human tear. As a source of biomarkers, the tear has been
used to assess the disease profiles of various ocular diseases, including, but not limited to, dry eye
disease, keratoconus, trachoma, and diabetic retinopathy, which have been reviewed elsewhere [181].
The majority of tear analysis studies have focused on the proteome as the relative amount of protein is
greater than metabolites. Along with this, a single technique is unable detect all tear metabolites due
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to no standardized collection, analysis, or identification methods. Despite this issue and not being in
direct contact with the retina, tears provide a non-invasive source of metabolomic biomarkers [182].
One of the first exclusive characterizations of the human tear metabolome aimed to use
a standard clinical method of tear collection and to develop an analytical platform, which could
be applied to characterize the global repertoire of human tear metabolites [180]. In this study, tears of
healthy individuals were collected using the clinically utilized Schirmer strips, separated by UFLC
(ultra-fast LC) and analyzed by Q-TOF MS/MS. This untargeted method of metabolite analysis
identified 60 metabolites from a range of 16 compound classes. Of these metabolites, 44 were ‘novel’ as
they did not correspond with metabolites identified in previous targeted studies (see Table 1 in [180]).
This set the precedent for what could be achieved in tear metabolome studies, but it was clear that this
method did not measure some well-known metabolites (e.g., measurement of glucose and ascorbic
acid was affected by background interference).
Very few lipid species were identified, but within the literature, others have identified
several classes of lipids using targeted analysis. These include free cholesterol [183],
phosphatidylcholines [183,184], SMs [183,184], wax esters [183,185], lysoPC [186,187], triacylglycerides,
ceramides, and phosphatidylethanolamines [186]. A further study investigated lipid composition
during collection with Schirmer strips using untargeted analysis [179]. Tears were collected either by
capillary tube or Schirmer strip and extracted lipids were analyzed using HPLC-MS. Over 600 lipid
species across 17 lipid classes were detected, the majority of which were categorized as either wax
esters or cholesteryl esters.
Contact of parts of the strip with the eye [188], particularly the meibum [189], clearly contributes
a large proportion of free cholesterols, sphingolipids, and phospholipids, and therefore the tear
lipidome is less complex than the meibum lipidome. These results were consistent with previous
studies investigating lipid classes in human tears, but this was the first extensive characterization
of the tear lipidome, where novel metabolites were also identified [179]. This includes cholesteryl
sulfates, which, as a stabilizing agent [190], could contribute to the amphiphilic sublayer of the tear film.
This study indicates the limitations of tear collection methodologies within the context of metabolomic
investigations. Schirmer strip collections yield the highest absolute amounts of lipids and are routinely
employed in the clinic. Although the level of background noise was high in blank Schirmer strips,
no endogenous tear lipids were detected [179]. Interestingly, the strips act as a chromatographic system
for lipid metabolites [179,186]. The aqueous fraction of the tear travels further along the strip than the
non-polar lipids. The strips can capture an accurate representation of the lipidomic profile of tears and
their relative concentrations when compared to spiking with artificial tear solutions [179]. It should be
noted that tears used in this study were obtained from patients with dry eye syndrome [179] and so
their metabolomic profiles and relative metabolite concentrations may differ from other patient groups.
Tear glucose levels have been considered as a non-invasive method of detecting the early stages
of diabetes [191] and they are increasingly being investigated for their use as a sensor for diabetes
mellitus [192]. It is well known that tear glucose levels are variable diurnally [193] and from which
eye the sample is taken [192]. However, there is evidence suggesting that the tear glucose levels
are reflective of blood glucose levels using enzyme-based and amperometric biosensors [194,195],
suggesting future clinical investigations of tear metabolites are worthwhile. However, there have been
questions raised as to the reliability of the results obtained and whether they are comparable to blood
glucose levels [196,197], and thus needs further investigation.
Tear samples appear to be a reasonable reservoir of metabolites, their collection is non-invasive,
and the samples are easy to handle and cheap to transport, indicating that tear sampling could
become a reliable source for metabolic markers for eye as well as other diseases [198]. Saliva has also
been studied as a source of potential biofluid metabolites [199–201], but there have been no studies
investigating the salivary metabolome in eye diseases.
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4.2. Vitreous and Aqueous Humor
In a similar manner to tears, the vitreous and aqueous humors might be a representative ocular
biofluid to use for metabolomics studies in AMD. Although they have to be obtained through invasive
procedures, often requiring collection during surgery, they are also being used as surrogate sources
of ocular disease biomarkers. Vitreous humor has been studied for metabolite changes in diabetic
retinopathy [202–207], proliferative vitreoretinopathy [207,208], rhegmatogenous retinal detachment
both associated and not associated with choroidal detachment [202,207–209], and uveitis [207].
Young et al. [207] investigated the metabolomic profiles of vitreous humor obtained from a variety
of inflammatory eye diseases. They were able to demonstrate clear and specific differences in
the metabolites obtained from each disease, with a high sensitivity in clinically relevant samples.
In a non-clinical context, vitreous humor from sheep, pigs, and rabbits was profiled using targeted
methods [210]. This revealed that acetylcholine esterase activity varied across species, but less so
between breeds of rabbit. Untargeted LC-MS analysis also found differences in metabolite profiles
that may simply reflect the diets of each animal, and this may have relevance to studies in humans.
However, it should be noted that, based on a study on rats, only 1.6% of the total metabolic profile
overlapped between the vitreous and the retina [133] although this might change in pathological states.
Aqueous humor has also been explored as a source of metabolite biomarkers in different diseases,
but the number of studies is more limited. In an acute model, glaucoma changes in glucose and citrate
levels were detected [211]. In a chronic glaucoma mice model, an increase of sphingolipid and ceramide
species was found [212]. Furthermore, in a chronic rat model for glaucoma, increases in acetoacetate,
citrate, and various amino acids, including alanine, lysine, and valine, as well as a decrease in glucose
levels, were found using 1H-NMR [213]. For acute and chronic glaucoma studies in human aqueous,
humor phospholipids [214], cholesterol [215], sphingolipid, and ceramide species [215,216] profiles
have been demonstrated to be dysregulated.
Aqueous humor has also been used in the identification of metabolic changes associated with
myopia [217,218]. Using a dual platform of capillary electrophoresis–mass spectrometry (CE-MS) and
LC-MS, one of the studies identified 40 metabolites [217]. Of these, 20 were deemed to be significantly
different between varying stages of myopia. Increases in arginine, citrulline, and sphinganine were
associated with high myopia while increases in aminoundecanoic acid and dihydro-retinoic acid were
associated with low myopia [217]. The other study used GC/TOF-MS and compared the metabolites
present in the aqueous humor of patients with high myopia and compared these to controls [218].
A total of 242 metabolites were identified, with significant increases observed in 27 and significant
decreases in two metabolites [218].
Metabolomic profiles in human aqueous humor have been compared with serum metabolites
from the same patients [219]. The most notable metabolite to differ between the two biofluids was
ascorbate, attributed to the ascorbate-specific pumps at the blood-aqueous border. Other differences
were attributed to the differential metabolic activity of the compartmentalized ocular tissues, but the
potential for post-mortem artefacts has also been raised [219]. Due to the invasiveness of obtaining
vitreous and/or aqueous humor, their use will probably be limited to those where surgical intervention
is a necessity.
4.3. In vivo Imaging
A different approach to obtaining metabolomic information, and of interest for retinal studies, is
the use of in vivo fluorescence imaging. Imaging approaches offer the advantages of data collection
with high spatial resolution, modest intervention, high safety, and low cost of data. Due to their
accessibility, the eye, and retina in particular, are well suited for optical studies compared to most
organs. This has fueled the development of numerous approaches for diagnosis and therapy in the
eye. Many metabolites highlighted in Table 1, and in previous sections, have little or no fluorescence
emission at wavelengths longer than 300 nm, nor unique IR nor Raman spectra, limiting the scope
of fluorescence imaging as a broad metabolomic approach. However, the nicotinamide adenine
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dinucleotide coenzyme NADP(H), and to a lesser extent flavin mononucleotide (FMN), flavin adenine
dinucleotide (FAD), and pyridoxal/pyridoxamine, exhibit useful visible fluorescence under certain
conditions [220]. These molecules are also intimately linked to numerous metabolic pathways and offer
information about metabolite fluxes through those pathways. Of interest are the nicotinamide adenine
dinucleotides, NAD(H) and NADP(H), which are the principal carriers of reducing equivalents
within cells. NAD(H) is crucial for energy production in the cell as it is the primary transporter
of electrons for oxidative phosphorylation, whereas NADP(H) provides the reducing equivalents
for the neutralization of cellular reactive oxygen species (ROS). The importance of NAD(H) to the
energetic state of cells was recognized decades ago, where the proportions of NAD(H) and NADH
were measured spectrophotometrically and by fluorescence [221]. Naturally, as a cell acquires energy
through different routes (oxidative phosphorylation, glycolysis, fermentation, reductive carboxylation)
and from different fuels (glucose, fatty acids, ketone bodies), different pathways are activated or
deactivated, and the broader metabolome will reflect this.
Recently, more powerful techniques have been developed to study NADP(H) and other
fluorophores. For example, the fluorescence emission spectra of NAD(H) and NADP(H), free in
solution, are very similar (a broad peak around 460 nm after excitation near 340 nm) and so the
proportions of each cannot be distinguished based on spectra alone. However, the reduced forms of
both exhibit different fluorescence lifetimes when free in solution and bound to proteins [222,223].
The fluorescence lifetime is the average amount of time the fluorophore spends in the excited state
between excitation and emission, and is typically in the range of nanoseconds [224]. This can either
be measured in the time domain with a technique known as time correlated single photon counting
(TCSPC) [225], or in the frequency domain by phase fluorometry [224]. While the lifetime is a general
property of each fluorophore, for some fluorophores, the lifetime is very sensitive to environmental
conditions. When free in solution, NAD(H) has a low quantum yield and a mixture of fluorescence
lifetimes between 0.3 and 0.8 nsec. When protein-bound, the lifetime ranges from 1.5 to 6 nsec.
The development of fluorescence lifetime-based imaging microscopy (FLIM) [224,225] made it possible
to collect specimen images where the contrast comes from differences in lifetime, not intensity.
Studies have appeared demonstrating that FLIM can distinguish between free and protein-bound
NAD(H) [226] and between intracellular NAD(H) and NADP(H) [227], a result not possible when only
detecting their spectrally identical fluorescence [228]. The metabolic state and composition of a tissue
can also be assessed by measuring the autofluorescence lifetime of endogenous fluorophores [229–232],
including protein-bound NADP(H) [223].
In in vitro studies, FLIM has been utilized to assess different structures within RPE cells [233],
as well as in retinal tissue from donors with AMD [234]. Miura et al. [233] identified that the
fluorescence lifetime observed inside and surrounding cultured RPE cells increases significantly
when oxidative stress is induced. This enabled the discrimination between the granules associated
with increases in metabolic stress from the melanosomes seen under normal conditions. From retinal
tissues [234], the RPE and BrM could be discriminated from one another using their fluorescence
lifetimes. This was primarily because of the presence of lipofuscin in the RPE, which had a shorter
lifetime than other emitters. Where it was present, drusen could also be discriminated from the RPE and
the BrM. In addition, it was found that different drusen had different lifetime distributions, indicating
that different fluorophores, or the same fluorophores in different environments, contribute to the FLIM
image [234]. Schweitzer et al. [234] also found lipofuscin-like FLIM signatures in structures within
drusen, which they interpreted as indicating a role of lipofuscin in the formation of sub-RPE deposits.
The analysis of the ocular fundus has been extended to include fluorescence lifetime imaging
ophthalmoscopy (FLIO), a technique analogous to FLIM [235]. Fluorophores that are interesting
for AMD are redox coenzymes, NAD(H) and FAD, as well as lipofuscin [236], AGEs [71],
and collagen. The excitation and emission spectra of these endogenous fundus fluorophores
have been investigated in vivo, which showed that it would not be possible to distinguish them
based on autofluoresecnce [231]. However, changes in fluorescence lifetime, especially when the
Metabolites 2019, 9, 4 22 of 36
metabolic environment is altered, could identify novel signatures that are associated with AMD [231].
When performing FLIO, it is worth considering the strong fluorescence of the lens [237], which cannot
be entirely suppressed, but which can be overcome using specific analysis software [238]. Multiphoton
excitation may help minimize such background fluorescence, but the safety considerations should be
made when utilizing focused, high peak power picosecond lasers for in vivo studies [239,240].
Following on from the in vitro observations described by Miura et al. [233], the in vivo FLIO has
also been utilized as a tool to investigate the effects of induced oxidative stress on RPE degeneration
and photoreceptor loss in a mouse model [241]. Following intravenous sodium iodate injection,
which induces RPE degeneration, the retinal autofluorescence lifetimes increased over a 28-day
period compared to control mice. In contrast, intraperitoneal injection of N-methyl-N-nitrosourea,
which causes the specific degeneration of the photoreceptors, resulted in shorter lifetimes being
observed [241]. From these results, the authors suggested that short lifetimes are present in the RPE,
but are altered with the overlying retinal structures. FLIO imaging has also been used to distinguish
AMD patients from controls [242]. It was found that images from AMD eyes had a significantly
longer retinal fluorescence lifetime, and they found that the lifetimes may vary from drusen to drusen,
although distinguishing drusen on FLIO images appears to be challenging [242]. Similar observations
were made in another study [243]. However, lifetime changes are present in 36% of the healthy controls,
which suggests these observations could be the result of aging [243]. Whether these fluorescence
lifetime changes are associated with the metabolomics changes mentioned above will need to be
investigated further.
The ability to distinguish between drusen subtypes and different structures in the retina is
complementary to the multimodal imaging approaches described previously [81,244]. These studies
indicate that fluorescence lifetime imaging approaches (FLIM and FLIO) could become tools for
studying not only the biology and metabolomics of the retina, but also the pathologic processes that
lead to diseases, such as AMD. Several comprehensive reviews detailing the principles of fluorescence
lifetime imaging and its application as a clinical tool has recently been published [245,246].
5. Conclusions
In summary, the complex repertoire of metabolites found in the retina is only beginning to be
revealed, and there is scope to identify those associated with the development of AMD. Clearly there
is a dysregulation of lipids in patients suffering from AMD, and various models exist for investigating
AMD biomarkers. Considering the close association between photoreceptor degeneration, RPE health,
sub-RPE deposit formation, and choroidal changes, it is perhaps not surprising to find lipids and
molecules associated with metabolic fluxes in the studies highlighted. Plasma metabolomics could
be a convenient tool for analyzing a wide range of factors potentially contributing to AMD, however,
the number of published studies compared to other ‘-omics’ methodologies still remains low [110].
Further efforts are clearly needed here whilst due consideration of the blood-retinal barrier is required.
It is still unclear whether the systemic biomarkers identified in biofluids can be representative of the
changes in the eye. Alternative biofluids, such as tear, saliva, and vitreous, are also viable possibilities
for detecting local and systemic changes in AMD patients.
Some of the current barriers associated with large-scale epidemiological metabolite studies are
being overcome by advances in technology for untargeted metabolite analysis [247]. Comprehensive
study design is crucial for high accuracy and good quality metabolomics data collection, which means
other potential limitations include, but are not limited to, subject selection, sample selection, collection,
handling, storage, and preparation [21,248]. As part of overcoming these limitations, it will become
necessary to establish reference lists of metabolites obtained from various biofluids in larger cohorts
of healthy, age-similar patients. Similar cell-based libraries are being developed for proteomic
integration [249]. For metabolomics, this will require additional advances in the analytical technologies,
as well as strong collaborations to systematically ensure a standardized benchmark can be obtained.
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The introduction and application of lifetime based clinical imaging with FLIO now allows
a non-invasive approach for the identification of metabolic changes in the retina. This is a new
methodology that needs further validation, but the potential to use this approach for clinical practice
is very appealing. Apart from the imaging of endogenous fluorophores, there is a possibility to deliver
markers that change their fluorescent lifetime once they are bound to specific metabolites. While this
approach is still in its infancy [250], once proven to be safe, it could provide new insight into the
metabolic machinery in health and diseases.
Apart from the comparisons between disease and control, it will be interesting to study metabolic
changes associated with dietary intervention in AMD [251,252]. A recent study on an animal model
investigated this [130]. Plasma and urine samples were obtained from wild-type mice, which were
fed diets with either a high- or low-glycemic index and subsequently analyzed by LC-MS and
proton NMR. A total of 330 metabolites were found in plasma and urine (309 in plasma, 47 in
urine, with 26 found in both). The mice fed the high-glycemic diet showed higher levels of lipids,
including phosphatidylcholine, C3 carnitine, and lysoPE. Higher levels of the protein derivatives
of 2-ω-carboxyethyl pyrrole (CEP) were also found [253,254]. These changes were associated with
dysfunction of the RPE and degradation of the retinal cell structures. Therefore, dietary studies relevant
for AMD can now be investigated both in animals and perhaps in humans [255].
Identifying biomarkers for such a multifactorial disease as AMD remains a significant challenge.
There are noticeable overlaps between risk factors for AMD and many other diseases (as reviewed by
Kersten et al. [17]). Therefore, metabolomics investigations can provide a further source of information
that can be integrated into distinguishing AMD from other comorbidities. Further studies will shed
light on potential metabolites, which may be used as early stage biomarkers, perhaps even being
applied as precision medicine tools in the future treatment of AMD [256–258].
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